Price$13.35+6.52 (+95.04%)
2026-03-042026-06-05
News · 26 weeks65-90%
2025-12-142026-06-07
Mix4790d
- Insider22(47%)
- SEC Filings11(23%)
- Other10(21%)
- Earnings3(6%)
- Analyst1(2%)
Latest news
25 items- SECSEC Form PREM14A filed by Organon & Co.PREM14A - Organon & Co. (0001821825) (Filer)
- SECSEC Form SD filed by Organon & Co.SD - Organon & Co. (0001821825) (Filer)
- PROrganon to Present New Research on Access and Value at ISPOR 2026New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women's health and general medicines portfolio Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women's health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect O
- INSIDERAmendment: SVP and Corporate Controller Holzbaur Lynette sold $353,080 worth of shares (26,448 units at $13.35) and acquired 46 shares, closing all direct ownership in the company (SEC Form 4)4/A - Organon & Co. (0001821825) (Issuer)
- INSIDERSVP and Corporate Controller Holzbaur Lynette bought $353,080 worth of shares (26,448 units at $13.35), increasing direct ownership by 100% to 52,851 units (SEC Form 4)4 - Organon & Co. (0001821825) (Issuer)
- SECSEC Form 10-Q filed by Organon & Co.10-Q - Organon & Co. (0001821825) (Filer)
- SECSEC Form SCHEDULE 13G filed by Organon & Co.SCHEDULE 13G - Organon & Co. (0001821825) (Subject)
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- SECOrganon & Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Organon & Co. (0001821825) (Filer)
- PROrganon Reports Results for the First Quarter Ended March 31, 2026First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") in an all-cash transaction (the "merger"). The merger is expected to close in early 2027, subject to customary closing conditions, inc
- PREuropean Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in EuropeSHANGHAI, April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE:OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 "As the first, and currently the only, pertuzumab biosimilar in Europe, the EC's approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Unio
- PROrganon Cancels First Quarter Earnings CallOrganon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company's April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue its first quarter financial results on April 30, 2026 in a press release, as well as in a subsequent Form 10-Q that it will file with the U.S. Securities and Exchange Commission ("SEC"). About Organon Organon (NYSE:OGN) is a global
- PREuropean Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in EuropeShanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE:OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ "As the first, and currently the only, pertuzumab biosimilar in Europe, the EC's approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as
- ANALYSTOrganon upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Organon from Underweight to Neutral and set a new price target of $14.00
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- SECOrganon & Co. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K - Organon & Co. (0001821825) (Filer)
- PRSun Pharma signs Definitive Agreement to Acquire OrganonOrganon stockholders to receive US$ 14.00 per share in cash The deal values Organon at EV of US$ 11.75 billion Combined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, "Sun Pharma") and Organon & Co. (NYSE:OGN) ("Organon") today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press r
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- SECSEC Form DEF 14A filed by Organon & Co.DEF 14A - Organon & Co. (0001821825) (Filer)
- PROrganon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will release its first quarter 2026 financial results on May 7, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the first quarter of 2026. Organon's first quarter results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing First Quarter 2026 Financial R
- PROrganon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic DermatitisThe American Academy of Dermatology (AAD) provided a strong, evidence-based recommendation for the use of VTAMA cream, the only steroid-free topical treatment the AAD found to be supported by a high certainty of evidence that is indicated across all severities in children aged 2 years and older with atopic dermatitis (AD) This recommendation reflects the proven efficacy, safety, and tolerability of VTAMA cream as a first-in-class, steroid-free, topical aryl hydrocarbon receptor (AhR) agonist for children and adolescents with AD AD, the most common form of eczema, impacts nearly 10 million children in the US Organon (NYSE:OGN), a global healthcare company with a mission to deliver
OGN FAQ
7 questionsWhat does Organon & Co. do?
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a...Where does OGN stock trade?
Organon & Co. (OGN) is listed on NYSE.What sector and industry is OGN in?
Organon & Co. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Organon & Co. go public?
Organon & Co. (OGN) completed its IPO in 2021.What are analysts saying about OGN?
Organon & Co. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral with a $1400.00 price target on 2026-04-28.What companies are similar to OGN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare OGN side-by-side with any of them on Quantisnow.How can I track OGN on Quantisnow?
Quantisnow aggregates Organon & Co.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OGN to receive live email and push alerts on every new disclosure.